<DOC>
	<DOCNO>NCT00681343</DOCNO>
	<brief_summary>To observe randomized prospective pilot study effectiveness toxicity Thymoglobulin vs. Campath-1H use induction therapy recipient live donor ( LD ) kidney , compare standard treatment protocol Zenapax® maintenance immunosuppression</brief_summary>
	<brief_title>Thymoglobulin Versus Campath-1H Versus Daclizumab Adult , Primary Living Donor Renal Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Calcineurin Inhibitors</mesh_term>
	<mesh_term>Daclizumab</mesh_term>
	<mesh_term>Immunoglobulin G</mesh_term>
	<criteria>1 . Patient fully inform sign date IRB approval inform consent form willing follow study procedure extent study ( 36 month ) . Parent legal guardian must provide write consent patient &lt; 18 year age . 2 . Age 1665 year 3 . Weight &gt; 40 kg 4 . Primary renal allograft : living relate ( non HLA identical ) unrelated donor 5 . Negative standard crossmatch Tcells . All donorrecipient pair match minimum 1 HLA DR antigen . ( Standard center ) 6 . Women childbearing potential require negative qualitative serum pregnancy test agree use adequate method contraception 3 month follow discontinuation Thymoglobulin Campath1H 7 . Males female study equivalently become available transplantation use criterion . 1 . Patient previously receive receive organ transplant kidney . 2 . Patient receive ABO incompatible donor kidney . 3 . Recipient donor seropositive human immunodeficiency virus ( HIV ) , Hepatitis C virus , Hepatitis B virus antigenemia . 4 . Patient current malignancy history malignancy ( within past 5 year ) , except nonmetastatic basal squamous cell carcinoma skin treat successfully carcinoma situ cervix treat successfully . 5 . Patients significant liver disease , define past 28 day continuously elevate AST ( SGOT ) and/or ALT ( SGPT ) level great 3 time upper value normal range center . 6 . Patient uncontrolled concomitant infection and/or severe diarrhea , vomit , active upper gastrointestinal tract malabsorption active peptic ulcer unstable medical condition could interfere study objective . 7 . Patient currently participate another clinical trial investigational drug 30 day prior transplant . 8 . Patient receive immunosuppressive agent prescribe study . 9 . Patient unable take medication orally via nasogastric tube morning second day follow completion transplant procedure ( i.e . skin closure ) . 10 . Patient receiving may require warfarin , fluvastatin herbal supplement study . 11 . Concurrent use astemizole , pimozide , cisapride , terfenadine , ketoconazole . 12 . Patient known hypersensitivity Tacrolimus , Campath1H , Thymoglobulin , Daclizumab ( Zenapax® ) , Sirolimus , MMF corticosteroid . 13 . Patient pregnant lactating . 14 . Patients screening/baseline ( within 96 hour transplant ) total white blood cell count &lt; 4000/mm3 ; platelet count &lt; 100,000/mm3 ; fast triglyceride &gt; 400 mg/dl ( &gt; 4.6 mmol/L ) ; fast total cholesterol &gt; 300 mg/dl ( &gt; 7.8 mmol/L ) ; fast HDLcholesterol &lt; 30 mg/dl ; fast LDLcholesterol &gt; 200mg/dl . 15 . Patient unlikely comply visit schedule protocol . 16 . Patient form substance abuse , psychiatric disorder condition , opinion investigator , may invalidate communication investigator . 17 . If tacrolimus institute longer 5 day postoperatively .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>Randomized</keyword>
	<keyword>study</keyword>
	<keyword>effectiveness/toxicity</keyword>
	<keyword>induction therapy</keyword>
	<keyword>recipient</keyword>
</DOC>